IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 1.55 (2012 - 2016). 

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
PIPPHARMACON & IJPR 2018

PIPPHARMACON & IJPR 2018

Click to download
 

Article Detail

Label
Label
COMPARISON OF SAFETY REPORTS: HIGH-RISK VERSUS LOW-RISK PATIENTS

Author: JUNY SEBASTIAN, ALISHA BESTO, RINUSHAJI, , T VIJAYALAKSHMI, MELAMBHA SURONG, M RAMESH
Abstract: To determine the incidence, causality, severity, predictability, preventability, seriousness, predictors and direct cost associated with the management of ADRs in high-risk and low-risk patients. The prospective study enrolled eligible patients in to high-risk and low-risk categories as per the developed criteria. Required data were collected whenever there was an ADR detected among the study population. Data was analyzed for incidence, causality (by Naranjo’s scale and WHO scale), severity (by Modified Hartwig and Siegel scale), predictability, preventability (by Modified Shumock and Thornton scale), seriousness (by ICH-GCP guidelines) and direct cost associated with the management of ADRs. The incidence of ADRs in high-risk patients was 11.28% and that of low-risk patients was 10.44%. Majority (56.56%) of highrisk patients who developed ADRs were females while 69.01% of low-risk patients who experienced ADRs were males. Drugs most commonly implicated in ADRs among high-risk patients were insulin (8.94%) followed by tramadol (6.50%) whereas among low-risk patients, ceftriaxone (15.06%) and insulin (10.95%) were the drugs implicated. Majority of the reaction were ‘probable’ in their causality category in both high-risk (82.1%) and low-risk patients (82.19%). A total of 99% of ADRs were ‘not preventable’ in both high-risk and low-risk groups. The incidence of ADR was equal in both high –risk and the low-risk group and there was no change in the severity and preventability of the reported ADRs. Therefore, early detection and prevention of ADRs in any patients are essential to avoid adverse outcomes of ADRs.
Keyword: Adverse Drug Reactions, High-risk, Low-risk, Predictors of ADRs.
DOI: https://doi.org/10.31838/ijpr/2018.10.03.008
Download: Request For Article
 












USER LOGIN


Username
Password
Login | Register
AICTE INTERNATIONAL CONFERENCE

AICTE Sponsored International Conference on Challenges, Opportunities and Newer Directions of Pharmacovigilance and Clinical Research in India

Download Brochure


For More Detail Visit www.pippharmacon.org
News & Events
hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477